Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Li Zhang, MD
Sun Yat-sen Univ. Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, China
- Beijing Chest Hospital, Capital Medical University
Beijing, China
- Peking University First Hospital
Beijing, China
- the First Hospital of Jilin University
Changchun, China
- Xiangya Hospital Central South University
Changsha, China
- Sichuan Cancer Hospital
Chengdu, China
- Chongqing University Cancer Hospital
Chongqing, China
- the Second Hospital of Dalian University
Dalian, China
- Fujian Medical University Union Hospital
Fuzhou, China
- Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (fuzhou Pulmonary Hospital of Fujian)
Fuzhou, China
- Guangdong Provincial People'S Hospital
Guangzhou, China
- Sun Yat-Sen University Cancer Center
Guangzhou, China
- Hainan General Hospital
Haikou, China
- First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
- Zhejiang Cancer Hospital
Hangzhou, China
- Zhejiang University School of Medicine, Sir Run Run Shaw Hospital
Hangzhou, China
- Harbin Medical University Cancer Hospital
Harbin, China
- Shandong Cancer Hospital
Jinan, China
- the First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
- Linyi Cancer Hospital
Linyi, China
- the First Affiliated Hospital of Nanchang University
Nanchang, China
- Guangxi Medical University Affiliated Tumor Hospital
Nanning, China
- Liaoning Cancer Hospital & Institute
Shenyang, China
- the First Hospital of China Medical University
Shenyang, China
- Peking University Shenzhen Hospital
Shenzhen, China
- the Fourth Hospital of Hebei Medical University
Shijiazhuang, China
- Shanxi Provincial Cancer Hospital
Taiyuan, China
- Tianjin Cancer Hospital Airport Hospital
Tianjin, China
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
- the Northern Jiangsu People'S Hospital
Yangzhou, China
- Yantai Yuhuangding Hospital
Yantai, China
- Henan Cancer Hospital
Zhengzhou, China
- Taipei Veterans General Hospital
Taipei, Taiwan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Jun 2022
- Primary completion
- 27 May 2024
- Completion
- 14 Dec 2026
- Last update posted
- 1 May 2026
- Registered enrollment
- 63
- Registry id
- NCT05195632
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.